R242
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 24
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.560
- ALLOGRAFT_REJECTION+0.550
- IL6_JAK_STAT3_SIGNALING+0.550
- INTERFERON_ALPHA_RESPONSE+0.550
- TNFA_SIGNALING_VIA_NFKB+0.550
- ANGIOGENESIS+0.540
- INTERFERON_GAMMA_RESPONSE+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- MTORC1_SIGNALING+0.470
- HEDGEHOG_SIGNALING+0.430
Top 10 suppressed
- KRAS_SIGNALING_DN-0.210
- PANCREAS_BETA_CELLS-0.180
- SPERMATOGENESIS-0.060
- ESTROGEN_RESPONSE_EARLY-0.030
- BILE_ACID_METABOLISM-0.020
- ESTROGEN_RESPONSE_LATE+0.020
- MYC_TARGETS_V2+0.030
- PEROXISOME+0.030
- DNA_REPAIR+0.060
- E2F_TARGETS+0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.942 |
| 2 | SRR934750 | — | — | 0.935 |
| 3 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.932 |
| 4 | SRR934782 | — | — | 0.927 |
| 5 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.923 |
| 6 | SRR934952 | — | — | 0.922 |
| 7 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.922 |
| 8 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.921 |
| 9 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.921 |
| 10 | TCGA-FD-A5BU-01A-31R-A26T-07 | — | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.420 | Idelalisib | — uncovered |
| APOPTOSIS | 0.410 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.390 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |